Neurotransmitter and Growth Factor Alterations in Functional Deficits and Recovery Following Traumatic Brain Injury

Brain Injury ◽  
2001 ◽  
pp. 267-294 ◽  
Author(s):  
Anthony E. Kline ◽  
Larry W. Jenkins ◽  
Hong Q. Yan ◽  
C. Edward Dixon
1995 ◽  
Vol 12 (2) ◽  
pp. 159-167 ◽  
Author(s):  
JAMES R. GOSS ◽  
SCOT D. STYREN ◽  
PETER D. MILLER ◽  
PATRICK M. KOCHANEK ◽  
ALAN M. PALMER ◽  
...  

2019 ◽  
Vol 25 (4) ◽  
pp. 1563-1572 ◽  
Author(s):  
Li Shan Chiu ◽  
Ryan S. Anderton ◽  
Jane L. Cross ◽  
Vince W. Clark ◽  
Neville W. Knuckey ◽  
...  

2014 ◽  
Vol 9 (1) ◽  
pp. 141 ◽  
Author(s):  
Yuqi Liu ◽  
Zongwei Liu ◽  
Xiaoming Li ◽  
Bangwei Luo ◽  
Jian Xiong ◽  
...  

2010 ◽  
Vol 31 (2) ◽  
pp. 658-670 ◽  
Author(s):  
Adel Helmy ◽  
Keri LH Carpenter ◽  
David K Menon ◽  
John D Pickard ◽  
Peter JA Hutchinson

The role of neuroinflammation is increasingly being recognised in a diverse range of cerebral pathologies, including traumatic brain injury (TBI). We used cerebral microdialysis and paired arterial and jugular bulb plasma sampling to characterise the production of 42 cytokines after severe TBI in 12 patients over 5 days. We compared two microdialysis perfusates in six patients: central nervous system perfusion fluid and 3.5% human albumin solution (HAS); 3.5% HAS has a superior fluid recovery (95.8 versus 83.3%), a superior relative recovery in 18 of 42 cytokines (versus 8 of 42), and a qualitatively superior recovery profile. All 42 cytokines were recovered from the human brain. Sixteen cytokines showed a stereotyped temporal peak, at least twice the median value for that cytokine over the monitoring period; day 1: tumour necrosis factor, interleukin (IL)7, IL8, macrophage inflammatory protein (MIP)1α, soluble CD40 ligand, GRO, IL1β, platelet derived growth factor (PDGF)-AA, MIP1β, RANTES; day 2: IL1 receptor antagonist (ra). IL6, granulocyte-colony stimulating factor (G-CSF), chemokine CXC motif ligand 10 (IP10); days 4 to 5: IL12p70, IL10. Brain extracellular fluid concentrations were significantly higher than plasma concentrations for 19 cytokines: basic fibroblast growth factor (FGF2), G-CSF, IL1α, IL1 β, IL1ra, IL3, IL6, IL8, IL10, IL12p40, IL12p70, IP10, monocyte chemotactic protein (MCP)1, MCP3, MIP1α, MIP1β, PDGF-AA, transforming growth factor (TGF)α and vascular endothelial growth factor. No clear arterio-jugular venous gradients were apparent. These data provide evidence for the cerebral production of these cytokines and show a stereotyped temporal pattern after TBI.


2010 ◽  
Vol 30 (5) ◽  
pp. 1008-1016 ◽  
Author(s):  
Orli Thau-Zuchman ◽  
Esther Shohami ◽  
Alexander G Alexandrovich ◽  
Ronen R Leker

Activation of endogenous stem cells has been proposed as a novel form of therapy in a variety of neurologic disorders including traumatic brain injury (TBI). Vascular endothelial growth factor (VEGF) is expressed in the brain after TBI and serves as a potent activator of angiogenesis and neurogenesis. In this study, we infused exogenous VEGF into the lateral ventricles of mice for 7 days after TBI using mini-osmotic pumps to evaluate the effects on recovery and functional outcome. The results of our study show that VEGF significantly increases the number of proliferating cells in the subventricular zone and in the perilesion cortex. Fate analysis showed that most newborn cells differentiated into astrocytes and oligodendroglia and only a few cells differentiated into neurons. Functional outcome was significantly better in mice treated with VEGF compared with vehicle-treated animals after TBI. Injury size was significantly smaller at 90 days after TBI in VEGF-treated animals, suggesting additional neuroprotective effects of VEGF. In conclusion, VEGF significantly augments neurogenesis and angiogenesis and reduces lesion volumes after TBI. These changes are associated with significant improvement in recovery rates and functional outcome.


Sign in / Sign up

Export Citation Format

Share Document